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Abstract
AIM
To analyze the clinicopathological characteristics of 
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patients with both node-negative gastric carcinoma and 
diagnosis of recurrence during follow-up. 
METHODS
We enrolled 41 patients treated with curative gast-
rectomy for pT2-4aN0 gastric carcinoma between 
1992 and 2010, who developed recurrence (Group 
1). We retrospectively selected this group from the 
prospectively collected database of 4 centers belonging 
to the Italian Research Group for Gastric Cancer, 
and compared them with 437 pT2-4aN0 patients 
without recurrence (Group 2). We analyzed lymphatic 
embolization, microvascular infiltration, perineural 
infiltration, and immunohistochemical determination 
of p53, Ki67, and HER2 in Group 1 and in a subgroup 
of Group 2 (Group 2bis) of 41 cases matched with 
Group 1 according to demographic and pathological 
characteristics.  
RESULTS
T4a stage and diffuse histotype were associated with 
recurrence in the group of pN0 patients. In-depth 
pathological analysis of two homogenous groups of 
pN0 patients, with and without recurrence during long-
term follow-up (groups 1 and 2bis), revealed two 
striking patterns: lymphatic embolization and perineural 
infiltration (two parameters that pathologists can easily 
report), and p53 and Ki67, represent significant factors 
for recurrence.
CONCLUSION
The reported pathological features should be con-
sidered predictive factors for recurrence and could be 
useful to stratify node-negative gastric cancer patients 
for adjuvant treatment and tailored follow-up.
Key words: N0 gastric cancer; Recurrence; Prognostic 
factors; Pathological analysis; Lymphatic embolization; 
Perineural infiltration; p53; Ki67
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Core tip: We analyze the clinicopathological cha-
racteristics of patients with both node-negative gastric 
carcinoma and diagnosis of recurrence during follow-
up in 4 Italian centers belonging to the Italian Research 
Group on Gastric Cancer between 1992 and 2010. 
Lymph node metastasis is the most important prognostic 
factor in patients undergoing radical surgery for gastric 
carcinoma. In-depth pathological analysis of two 
homogenous groups of pN0 patients, with and without 
recurrence during long-term follow-up, revealed two 
striking patterns: lymphatic embolization and perineural 
infiltration (two parameters that pathologists can easily 
report), and p53 and Ki67, represent significant factors 
for recurrence. The reported pathological features 
should be considered predictive factors for recurrence 
and could be useful to stratify node-negative gastric 
cancer patients for adjuvant treatment and tailored 
follow-up.
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INTRODUCTION
Nodal metastases are a well-known prognostic factor 
after radical treatment of gastric cancer. Although 
patients with adequately staged pN0 cancer have a 
good prognosis and usually do not undergo adjuvant 
chemotherapy, nevertheless a subset of them has a 
recurrence and, later, dies of this disease. Therefore, 
the identification of prognostic factors for cancer 
recurrence becomes extremely important for the 
identification of the small proportion of cases at risk for 
recurrence.
In some published studies focusing on the clinical-
pathological features and prognostic factors of node-
negative gastric cancer patients, surgical approaches 
were not homogenous, particularly in terms of lymph 
node dissection[1-10]. Other limitations were a too short 
follow-up, as well as the inclusion of T1 cases and of 
patients with less than 15 retrieved nodes. A previous 
multicentric series, which we published as members of 
the Italian Research Group for Gastric Cancer (GIRCG), 
studied 301 patients from 7 Italian centers[11]. These 
patients were treated during a 10-year period from 
1992 to 2002, underwent almost 5 years of regular 
follow-up, and about 10% developed tumor recurrence. 
The much valuable feedback and insightful suggestions 
of peer-reviewers, who have refereed our earlier article, 
inspired our next project and current paper. Those peer-
reviewers strongly encouraged us to carry out an in-
depth pathological analysis of the subgroup of patients 
experiencing recurrence despite having negative nodes 
on e-e staining; this group clearly represents a very 
interesting sample for a biological study. 
MATERIALS AND METHODS
The 4 Italian centers participating in this study were 
the University of Brescia, the Forlì Morgagni Pierantoni 
Hospital, the University of Siena, and the University of 
Verona. Inclusion criteria were patients with pN0 gastric 
carcinoma, treated during the period 1992-2010, 
who developed cancer recurrence during the 5-year 
follow-up. All patients had more than 15 retrieved 
nodes analyzed after surgery, all resulting negative 
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for metastases at routine hematoxylin-eosin stain-
ing. Exclusion criteria were (1) patients with gastric 
stump cancer; (2) patients with T1 or T4b tumors or 
peritoneal dissemination; (3) patients with fewer than 
15 retrieved nodes; and (4) patients who underwent 
pre- or post-operative chemotherapy. As a result, out 
of 1725 patients who underwent radical gastrectomy 
for T2-T4a gastric cancer, 478 patients without lymph 
node metastases were studied, and among those 41 
developed tumor recurrence (8.57%, Group 1) after a 
mean period of 17 months (range 9-89). Control group 
comprises the remaining 437 pN0 patients who did not 
develop cancer recurrence (Group 2). 
We then performed a retrospective review of 
prospectively collected data, taking into account 
patient’s age, sex, tumor markers CEA and CA 19.9 
when available, tumor size, tumor location (upper/
medium/lower third), depth of tumor invasion (T2/
T3/T4a), histological grading (G1/G2/G3), Lauren 
histotype (intestinal/diffuse/mixed or other), the type 
of operation (subtotal, GST/total gastrectomy, GT), 
the number of retrieved nodes, associated resections, 
post-operative major morbidity, and post-operative 
mortality. Survival rate was reported as mean + SD. 
We adopted the 2012 American Joint Committee 
on Cancer (AJCC) TNM staging system[12], whereas 
histological evaluation was performed according to the 
Japanese General Rules for Gastric Cancer Study in 
Surgery and Pathology[13]. 
We discontinued the enrollment of patients on 
the 31st of December, 2010, whereas we conducted 
follow-up until the 31st of December, 2015 or until the 
patient’s death. The median follow-up interval for 313 
patients, who were alive at the cut-off date, was 113.4 
months (range, 61-178 mo). Twenty-one patients 
(4.39%) had been lost to follow-up. There were 9 
(1.99%) in-hospital deaths. Lost cases and operative 
mortality cases were censored for the analysis of 
survival.
For in-depth histological analysis, we selected a 
subgroup (Group 2bis) of 41 controls from Group 2 
from one of the four centers participating to our study 
(the University of Brescia), matched with Group 1 
according to age, sex, tumor size, tumor location, tumor 
invasion (T), histological grading (G), Lauren histotype, 
and the number of retrieved nodes. We selected 
cases from the database of the University of Brescia. 
The same pathologist (CB) retrieved and analyzed 
all the specimens of tumors from Group 1 and Group 
2bis, and recorded lymphatic embolization, as well as 
microvascular and perineural infiltration, expressed 
as present/absent. Also, p53, Ki67, and HER2 were 
studied using immunohistochemical analysis, performed 
on formalin-fixed, paraffin-embedded sections of 
surgical specimens with commercially available primary 
antibodies Abcam anti-ErbB2 (CB11)ab8054, MIB-5 
(DAKO) for ki67 and Clone BP-53-12 (Genemed 
Biotechnologies, United States, 1:150) for p53. For 
HER2 evaluation, the following classification was used: 0, 
1+, 2+, 3+ for < 10%, > 10% partial staining, > 10% 
moderately complete staining, and > 10% intensely 
complete staining, respectively; 0 and 1+ were 
considered negative testing, 2+ and 3+ positive testing. 
The presence of p53 and ki67 was expressed by nuclear 
staining: the rate was calculated as the number of 
positive nuclear reactions over 100 cells, and for every 
case a final expression rate was estimated. 
Statistical analysis
We classified variables as discrete (gender, tumor 
markers, location, T, histotype, grading, associated 
resections, post-operative morbidity and mortality, 
lymphatic embolization, vascular infiltration, perine-
ural infiltration, HER2), or continuous (age, size, the 
number of retrieved nodes, p53, Ki67). We used χ2 and 
the Student t test to evaluate the statistical significance 
of differences for discrete and continuous variables, 
respectively. We then computed survival rates using 
the Kaplan-Meier method. P values less than 0.05 
were considered statistically significant. The statistical 
methods of this study were reviewed by Professor 
Giovanni Parrinello (Department of Biotechnologies, 
Section of Medical Statistics, University of Brescia, 
Italy). 
RESULTS
Table 1 summarizes the clinical and pathological 
features of pN0 patients. They represent a typical 
Western series, with a significant rate of diffuse or 
mixed (34.0%) and proximal (35.8%) cancers. At 
the same time, N0 patients had most frequently T2 
(60.2%) and G1-2 (72.2%) neoplasms, compared to 
the general gastric cancer population. The standard 
lymphadenectomy was D2, with a mean number 
of retrieved nodes equal to 26.2. However, this 
data should be interpreted taking into account the 
exclusion from the analysis of patients with less than 
15 retrieved nodes. Less than 10% of the patients 
underwent associated splenectomy, whereas pancreas 
tail resection was done in only 7 cases. Major morbidity 
rate was 12.7% and included 9 cases of anastomotic 
and 3 cases of duodenal leak (3 of these complications 
required re-intervention), 8 subphrenic abscesses 
(all treated by percutaneous drainage), 4 pancreatic 
fistula, 2 splenic necroses requiring splenectomy, 
3 postoperative hemorrhages, and 7 mechanical 
occlusions requiring re-intervention. Nine patients 
(1.88% of the sample) died before hospital discharge 
(8 because of surgical complications and 1 because of 
myocardial infarction).   
Of the whole series of N0 patients, 41 developed 
cancer recurrence during the follow-up. Table 2 
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significant in predicting recurrence; microvascular 
infiltration was not. Moreover, immunohistochemical 
study of p53, Ki67, and HER2 revealed that p53 and 
Ki67 were expressed in a significantly greater rate of 
cancer cells of patients who subsequently developed 
cancer recurrence, while this was not true for HER2.
At the time of the analysis, 313 (65.5%) patients 
were alive and free of disease, including 2 patients 
having a recurrence that was surgically treated with 
success (hepatic metastasis resection and total 
gastrectomy for gastric stump recurrence), 39 patients 
(8.15%) had died because of cancer recurrence, 
whereas 96 patients (20.0%) had died of other 
diseases. The remaining patients had died after surgery 
(9) or lost at follow-up (21). Due to the long period of 
follow-up after ending the recruitment of patients, no 
patient with recurrence is currently alive. Mean and 
median survival times were 93.4 and 81.1 months, 
respectively. The 3, 5, and 10-year overall survival and 
cancer-related survival rates of the whole group were 
79.2%, 72.6%, 41.4% and 91.7%, 87.2%, 76.8%, 
respectively.  
DISCUSSION
As mentioned earlier, the helpful feedback and sug-
gestions of peer-reviewers, who have refereed an 
earlier article of ours[11] based on an Italian multicentric 
series of patients with pN0 gastric cancer, inspired our 
next project and current paper. Those peer-reviewers 
encouraged us to carry out an in-depth pathological 
analysis of the subgroup of patients experiencing 
recurrence despite having negative nodes on e-e 
staining; this group clearly represents a very interesting 
sample for a biological study. Meanwhile, the increased 
number of available pN0 cases also enabled us to 
perform a confirmation analysis of the significant 
clinico-pathological basic factors found in our earlier 
study.  
In our current study we present a large, multi-
centric series of pN0 patients with gastric cancer, who 
have undergone radical surgery with reliable nodal 
harvesting (more than 15 analyzed nodes). Our main 
goal is to investigate which factors, easily available 
after standard pathological examination, are related 
to a higher likelihood of recurrence; this information 
is clearly very valuable to both the oncologists when 
deciding whether to use adjuvant chemotherapy, and 
the referring physicians when planning the targeted 
follow-up. 
The secondary but potentially equally relevant 
purpose of our study is to discover if an in-depth patho-
logical analysis, including three ancillary ematoxilin-
eosin data (lymphatic embolization, microvascular 
infiltration, and perineural infiltration) and three 
immunohistochemical examinations (p53, Ki67, and 
HER2) may add valuable information for such clinical 
shows the comparison between Group 1 (N0 patients 
with recurrence) and Group 2 (N0 patients with no 
recurrence). Significant prognostic factors for recurrence 
in N0 patients were T4a and diffuse histotype, while 
gender, age, tumor markers, location, size, grading, the 
number of retrieved nodes, associated resections, and 
major complications were not. Of the 41 patients with 
cancer recurrence, 11 developed their recurrence during 
the first year after surgery, 16 during the second year, 8 
during the third, and 6 in the following years. The sites 
of recurrence were liver in 21 cases, peritoneum in 27 
cases, loco-regional/lymphatic in 7 cases, and other 
sites in 5 cases. In only 2 cases, cancer recurrence was 
treated by surgery with potentially radical intent; other 
23 patients underwent palliative chemotherapy. 
Table 3 reports the comparison between Group 1 
(41 N0 patients with recurrence) and Group 2bis (41 
N0 patients without recurrence, matched to those of 
Group 1 according to demographic and pathological 
characteristics), for which we carried out in-depth 
histological analysis. Lymphatic embolization and 
perineural infiltration, which are histological parameters 
usually available with e-e staining, resulted highly 
Table 1  Clinical, pathological, and surgical features of 478 
N0 gastric cancer patients n  (%)
Values
Male 291 (60.9)
Female 187 (39.1)
mean age (range) 67.1 (31-90)
Tumor markers1 (positive) 33/282
Tumor location
   Upper   67 (14.1)
   Middle 104 (21.7)
   Lower 261 (55.6)
   Multiple   46 (9.6)
Tumor mean size (range), cm 4.311 (0.8-14)
Tumor invasion (T)
   T2 278 (58.2)
   T3 181 (37.8)
   T4a   19 (4.0)
Lauren histotype
   Intestinal 315 (65.9)
   Diffuse   81 (16.9)
   Mixed / Unavailable   82 (17.1)
Histological grading (G)
   G1   87 (18.2)
   G2 287 (60.0)
   G3 104 (21.8)
Type of surgery
   Subtotal gastrectomy 266 (55.7)
   Total gastrectomy 212 (44.3)
Mean retrieved node number2 26.2
   (range) (15-85)
Associated resections 53 (11.1)
   (splenectomies) [41 (8.5)]
30-d mortality 9 (1.88)
Major morbidity 61 (12.7)
1CEA and/or CA19.9 above the normal values of 7 ng/mL and 36 UI/mL, 
respectively; 2This value reflects the exclusion from our analysis of patients 
with less than 15 retrieved nodes.
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decisions. Pathologists do not typically analyze those 
6 ancillary data; however, these additional data, which 
are very easy and relatively inexpensive to analyze, 
may provide extremely helpful information in addition 
to the one from the basic pathological items.
We defined the study group taking into account the 
shortcomings of previous Western studies about node-
negative gastric cancer patients, and, hence, excluding 
T1, T4b, and Nx patients. T1N0 patients have a very 
good outcome, thus making adjuvant chemotherapy 
unlikely to be valuable. In contrast, T4b patients 
usually undergo a kind of adjuvant therapy (chemo- 
or radiotherapy) irrespective of other pathological 
parameters. Patients with less than 15 retrieved nodes 
are not adequately staged, so we cannot define them 
N0 patients. 
Factors associated with recurrence in N0 patients 
were only T4a and diffuse histotype. Nine out of 19 
patients with a true, pathologically proven serosal and 
extragastric fat infiltration experienced recurrence 
(47.3%), mainly peritoneal (6/9 cases) and nodal (5/9 
cases); this subgroup is thus suitable for adjuvant 
therapy. Therefore, T3 diffuse cases should also be 
considered for adjuvant therapy and intensive follow-
up, considering that about a quarter of them will 
experience recurrence. 
The most striking result of our study is that lym-
phatic embolization and perineural infiltration are 
significant parameters associated with recurrence in 
pN0 gastric cancer.[14] Out of 41 patients experiencing 
recurrence, 34 and 21 had lymphatic embolization 
and perineural infiltration, respectively. In Group 
1 + Group2bis (82 cases), 15 patients had both 
parameters, and 10 of them subsequently developed 
Table 2  Prognostic factors for recurrence in N0 gastric cancer patients
Group 1 (with recurrence) Group 2 (no recurrence) P  value3
(n  = 41) (n  = 437)
Gender (male) 28 263 0.308
Age (> 65) 19 201 0.966
Tumor markers1 6/25 27/207 0.138
Tumor location (upper)   7   60 0.555
Tumor size (> 5 cm) 16 132 0.242
Tumor invasion (T)
   T2 19 259 0.108
   T3 13 168 0.395
   T4a   9   10 0.001
Lauren histotype
   Intestinal 24 291 0.768
   Diffuse 12   69 0.012
   Mixed / Unavailable   5   77 0.509
Histological grading (G)
   G1   7   80 0.844
   G2 22 265 0.382
   G3 12   92 0.222
Retrieved nodes2 (mean) > 25 26 273 0.905
Associated resections - yes   8   45 0.772
Major morbidity - yes   8   53 0.175
1Almost 1 tumor marker positive, including CEA, CA 19.9, or other tumor marker. Only 282 cases were available for analysis; 2This value reflects the 
exclusion from our analysis of patients with less than 15 retrieved nodes; 3P values of χ 2 test for gender, tumor markers, tumor location, tumor invasion (T), 
Lauren histotype, histological grading (G), associated resections, post-operative morbidity. P values of Student t-test for age, tumor size, and the number of 
retrieved nodes. 
Table 3  Histological assessment of N0 patients with and without cancer recurrence, matched according to demographic and 
pathological characteristics
Group 1 (41 N0 patients with recurrence) Group 2bis (41 N0 patients without recurrence) P  value3
Lymphatic embolization 34 13 0.001
Microvascular infiltration 11   7 0.285
Perineural infiltration 19   6 0.001
p531 49.1% (0-100) 33.8% (0-100) 0.041
Ki671 52.7% (30-80) 33.1% (15-70) 0.038
HER22   7   8 0.785
1Our immunohistochemical analysis of p53 and Ki67 differ from some of those found in other studies because we expressed them as the number of cancer 
cells showing immunohistochemical staining over 100 cells, thus as a rate and not as a binomial variable (yes/no). Statistical analysis was retrospectively 
performed by Student t-test; 2Immunohistochemical detection, both 2+ and 3+ were considered positive; 3P values of χ 2 test for lymphatic embolization, 
microvascular infiltration, perineural infiltration, and HER2. P values of Student t-test for p53 and Ki67. 
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cancer recurrence (66.6%). In our earlier article 
including 301 patients from the same 4 Italian cen-
ters[11], data on these parameters were available for 
only 144 patients (confirming that basic pathological 
analysis does not typically provide information on 
these parameters); however, the 3 parameters were 
considered all together, with a rate of positive cases 
(26.3%) similar to the previously reported rate of 
about 20% of cases for microvascular infiltration and 
about 30% for perineural infiltration; they were not 
significantly related to the recurrence rate both at 
univariate and multivariate analysis. 
According to the Japanese classification of gastric 
carcinoma[15], further research to classify lymphatic 
invasion and venous invasion into three more specific 
grades would help clarify the association between 
these anatomo-pathological characteristics of tumor 
and the rate of recurrence. Also, a further study in 
which also a subgroup among non-T4a and intestinal 
histotype are added, would provide a more in-depth 
analysis of prognostic factors of recurrence.
From an immunohistochemical point of view, the 
p53 protein, encoded by a tumor suppressor gene 
located on the short arm of chromosome 17, is 
involved in different cell functions, including apoptosis 
and cell cycle regulation[16]. This protein is usually 
poorly expressed in normal cells, but overexpressed 
and/or mutated in a number of human malignancies[17]; 
overexpression of p53 generally reflects an underlying 
mutation(s) in the p53 gene[16]. A correlation among 
high protein levels, older age, advanced stage, and 
poor prognosis has been shown for colorectal, breast, 
and lung carcinoma[18]. Studies that have evaluated 
p53 expression and/or mutation in gastric cancer, 
have confirmed enhanced expression in cancer cells 
in comparison with normal cells (33.8% vs 4% in the 
series published by Zhou and Coll), but the bench-
mark value is different, ranging from 19%-29%[19] to 
34%-65%[20,21]; however, correlation of p53 expression 
and worse prognosis was shown in some[16,22], but not 
in other series[23]. 
Antigen KI-67 (Ki67) is a nuclear proliferation 
associated antigen, involved in cycle regulation and 
cell proliferation. It is considered a reliable marker 
of tumor biology, having a clear prognostic value 
in several types of cancer, such as GIST[24]; in two 
recent retrospective analyses of patients with gastric 
cancer, Ki67 expression was associated with distant 
metastasis and survival[25], T stage and 3-year disease 
free survival[26]. 
Human epidermal growth factor receptor 2 (HER2) 
is a transmembrane tyrosine kinase receptor, a 185 
kDa glycoprotein encoded by a gene located in the long 
arm of chromosome 17. HER2 is involved in various 
cancerogenesis steps, including de-differentiation, 
angiogenesis, and metastasis[27]. As noticeably shown 
in the case of breast cancer, expression of HER2 is 
a marker of more aggressive behavior and may be 
related to a worse prognosis compared with HER2 
negative tumors. In gastric cancer, an overexpres-
sion of HER2 has been reported in approximately 
10%-30% of cases; however, a clear relationship with 
histopathological parameters or survival has not been 
established[28,29]. A comprehensive literature review 
published in 2011[30] confirmed the lack of association 
between HER2 overexpression and patient-related, 
as well as cancer-related, main parameters. Other 
small series, however, suggested an association with 
older age, larger tumors, and advanced stage[31,32]. 
Our results clearly confirm that HER2 overexpression, 
determined only by immunohistochemical analysis 
and not by FISH method, is not related to a greater 
risk of cancer recurrence in pN0 cases. The overall 
expression of HER2 in the whole series is similar to the 
one previously reported, with a marginal proportion of 
cases having a clear 3+ overexpression; none of the 
41 patients with recurrence had 3+ HER2 expression, 
and the sum of 3+ and 2+ was also greater in group 
2bis (i.e., patients without recurrence). 
In conclusion, despite a good overall prognosis, 
about 10% of pN0, R0 gastric cancer patients actually 
have cancer recurrence and die of this disease. The 
prognostic factors analyzed and reported in our study 
may help identify node-negative patients who would 
significantly benefit from existing or future adjuvant 
strategies. Moreover, for these patients an appropriate 
surveillance protocol in terms of follow-up should be 
proposed. 
Further research with extra pathological examin-
ations could be useful to define an algorithm for the 
management of pN0 gastric cancer patients.
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